Cancer Research Meeting Calendar Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 720-727, February 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagnato, A.
Right arrow Articles by Natali, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagnato, A.
Right arrow Articles by Natali, P. G.
[Cancer Research 59, 720-727, February 1, 1999]
© 1999 American Association for Cancer Research

Tumor Biology

Expression of Endothelin 1 and Endothelin A Receptor in Ovarian Carcinoma

Evidence for an Autocrine Role in Tumor Growth1

Anna Bagnato2, Debora Salani, Valeriana Di Castro, Jinshyun R. Wu-Wong, Raffaele Tecce, Maria Rita Nicotra, Aldo Venuti and Pier Giorgio Natali

Laboratories of Molecular Pathology and Ultrastructure [A. B., D. S., V. D. C., R. T.], Virology [A. V.], and Immunology [P. G. N.], Regina Elena Cancer Institute, 00158 Rome, Italy; Biotechnology Institute, Consiglio Nazionale delle Ricerche, 00161 Rome, Italy [M. R. N.]; and Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, Illinois 60064-3500 [J. R. W-W.]

In the present study, we have investigated the expression of endothelin 1 (ET-1) and the ETA receptor (ETAR) and ETB receptor (ETBR) in primary (n = 30) and metastatic (n = 8) ovarian carcinomas and their involvement in tumor growth. By reverse transcription-PCR and Northern blot analysis, we detected ET-1 mRNA in 90% of primary and 100% of metastatic ovarian carcinomas. ET-1 mRNA expression was significantly higher in tumors than in normal ovarian tissues (n = 12; P < 0.01). ETAR mRNA was also detected in 84% of the carcinomas examined, whereas ETBR mRNA was expressed in 50% of the tumors. The in vivo presence of mature ET-1 and ETAR was confirmed by immunohistochemistry, demonstrating a higher expression in primary and metastatic cells. Ten primary cultures of ovarian tumors secreted ET-1 and were positive for ET-1 and ETAR mRNA, whereas only 40% expressed ETBR mRNA. Radioligand binding studies showed that ET-1-producing cells also expressed functional ETAR, whereas no specific ETBR could be demonstrated. ET-1 stimulated dose-dependent [3H]thymidine incorporation and enhanced the mitogenic effect of epidermal growth factor. The ETAR-selective antagonist BQ 123 strongly inhibited ET-1-stimulated growth and substantially reduced the basal growth rate of unstimulated cells, whereas the ETBR-selective antagonist BQ 788 had no effect. In conclusion, the present data demonstrate a novel mechanism in the growth control of ovarian carcinoma in vivo mediated by the ET-1 autocrine loop that selectively occurs via the ETAR.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
O. Rayhman, E. Klipper, L. Muller, B. Davidson, R. Reich, and R. Meidan
Small Interfering RNA Molecules Targeting Endothelin-Converting Enzyme-1 Inhibit Endothelin-1 Synthesis and the Invasive Phenotype of Ovarian Carcinoma Cells
Cancer Res., November 15, 2008; 68(22): 9265 - 9273.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Chiappori, E. Haura, F. A. Rodriguez, D. Boulware, R. Kapoor, A. M. Neuger, R. Lush, B. Padilla, M. Burton, C. Williams, et al.
Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2008; 14(5): 1464 - 1469.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
G. M Tse, B. Chaiwun, K.-M. Lau, R. Scolyer, C S. Lee, R. Z Karim, T. C Putti, B. K Law, P. C Lui, and P. H. Tan
Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours
J. Clin. Pathol., September 1, 2007; 60(9): 1051 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Rosano, V. Di Castro, F. Spinella, G. Tortora, M. R. Nicotra, P. G. Natali, and A. Bagnato
Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity
Cancer Res., July 1, 2007; 67(13): 6351 - 6359.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Rosano, V. Di Castro, F. Spinella, M. R. Nicotra, P. G. Natali, and A. Bagnato
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo
Mol. Cancer Ther., July 1, 2007; 6(7): 2003 - 2011.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M J Grimshaw
Endothelins and hypoxia-inducible factor in cancer
Endocr. Relat. Cancer, June 1, 2007; 14(2): 233 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Van Sant, G. Wang, M. G. Anderson, O. J. Trask, R. Lesniewski, and D. Semizarov
Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway
Mol. Cancer Ther., January 1, 2007; 6(1): 253 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
F. Spinella, L. Rosano, S. Decandia, V. Di Castro, A. Albini, G. Elia, P. G. Natali, and A. Bagnato
Antitumor Effect of Green Tea Polyphenol Epigallocatechin-3-Gallate in Ovarian Carcinoma Cells: Evidence for the Endothelin-1 as a Potential Target.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1123 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. Rosano, F. Spinella, V. Di Castro, S. Decandia, M. R. Nicotra, P. G. Natali, and A. Bagnato
Endothelin-1 Is Required During Epithelial to Mesenchymal Transition in Ovarian Cancer Progression.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1128 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. Speciale, R. Biffi, R. Mancuso, E. Borghi, R. Mazziotti, and P. Ferrante
Big endothelin-1 and interleukin-6 modulation in human microvascular endothelial cells after human herpesvirus 8 infection.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1171 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Spinella, L. Rosano, V. Di Castro, S. Decandia, A. Albini, M. R. Nicotra, P. G. Natali, and A. Bagnato
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
Mol. Cancer Ther., June 1, 2006; 5(6): 1483 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Rosano, F. Spinella, V. Di Castro, S. Dedhar, M. R. Nicotra, P. G. Natali, and A. Bagnato
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.
Mol. Cancer Ther., April 1, 2006; 5(4): 833 - 842.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Rosano, F. Spinella, V. Di Castro, M. R. Nicotra, S. Dedhar, A. G. de Herreros, P. G. Natali, and A. Bagnato
Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells
Cancer Res., December 15, 2005; 65(24): 11649 - 11657.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Bagnato, F. Spinella, and L. Rosano
Emerging role of the endothelin axis in ovarian tumor progression
Endocr. Relat. Cancer, December 1, 2005; 12(4): 761 - 772.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kajiyama, K. Shibata, M. Terauchi, T. Morita, K. Ino, S. Mizutani, and F. Kikkawa
Neutral Endopeptidase 24.11/CD10 Suppresses Progressive Potential in Ovarian Carcinoma In vitro and In vivo
Clin. Cancer Res., March 1, 2005; 11(5): 1798 - 1808.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
P. Robin, S. Chouayekh, C. Bole-Feysot, D. Leiber, and Z. Tanfin
Contribution of Phospholipase D in Endothelin-1-Mediated Extracellular Signal-Regulated Kinase Activation and Proliferation in Rat Uterine Leiomyoma Cells
Biol Reprod, January 1, 2005; 72(1): 69 - 77.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Spinella, L. Rosano, V. Di Castro, P. G. Natali, and A. Bagnato
Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion
J. Biol. Chem., November 5, 2004; 279(45): 46700 - 46705.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato
Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells
Clin. Cancer Res., July 15, 2004; 10(14): 4670 - 4679.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. W. Ryan, N. J. Vogelzang, E. E. Vokes, H. L. Kindler, S. D. Undevia, R. Humerickhouse, A. K. Andre, Q. Wang, R. A. Carr, and M. J. Ratain
Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies
Clin. Cancer Res., July 1, 2004; 10(13): 4406 - 4411.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Bagnato, L. Rosano, F. Spinella, V. Di Castro, R. Tecce, and P. G. Natali
Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression
Cancer Res., February 15, 2004; 64(4): 1436 - 1443.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato
Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells
J. Biol. Chem., October 17, 2003; 278(42): 41294 - 41301.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
V. Chhokar and A. L. Tucker
Angiogenesis: Basic Mechanisms and Clinical Applications
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Zonnenberg, G. Groenewegen, T. J. Janus, T. W. Leahy, R. A. Humerickhouse, J. D. Isaacson, R. A. Carr, and E. Voest
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan: An Endothelin Receptor Antagonist for Refractory Prostate Cancer
Clin. Cancer Res., August 1, 2003; 9(8): 2965 - 2972.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Rosano, F. Spinella, D. Salani, V. Di Castro, A. Venuti, M. R. Nicotra, P. G. Natali, and A. Bagnato
Therapeutic Targeting of the Endothelin A Receptor in Human Ovarian Carcinoma
Cancer Res., May 15, 2003; 63(10): 2447 - 2453.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Carducci, R. J. Padley, J. Breul, N. J. Vogelzang, B. A. Zonnenberg, D. D. Daliani, C. C. Schulman, A. A. Nabulsi, R. A. Humerickhouse, M. A. Weinberg, et al.
Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
J. Clin. Oncol., February 15, 2003; 21(4): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. J. Grimshaw, S. Naylor, and F. R. Balkwill
Endothelin-2 Is a Hypoxia-induced Autocrine Survival Factor for Breast Tumor Cells
Mol. Cancer Ther., December 1, 2002; 1(14): 1273 - 1281.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Spinella, L. Rosano, V. Di Castro, P. G. Natali, and A. Bagnato
Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1alpha in Ovarian Carcinoma Cells
J. Biol. Chem., July 26, 2002; 277(31): 27850 - 27855.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Carducci, J. B. Nelson, M. Kathy Bowling, T. Rogers, M. A. Eisenberger, V. Sinibaldi, R. Donehower, T. L. Leahy, R. A. Carr, J. D. Isaacson, et al.
Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics
J. Clin. Oncol., April 15, 2002; 20(8): 2171 - 2180.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Aleksic, Z. Szabo, U. Scheffel, H. T. Ravert, W. B. Mathews, L. Kerenyi, P. A. Rauseo, R. E. Gibson, H. D. Burns, and R. F. Dannals
In Vivo Labeling of Endothelin Receptors with [11C]L-753,037: Studies in Mice and a Dog
J. Nucl. Med., August 1, 2001; 42(8): 1274 - 1280.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Ali, M Loizidou, M Dashwood, F Savage, C Sheard, and I Taylor
Stimulation of colorectal cancer cell line growth by ET-1 and its inhibition by ETA antagonists
Gut, November 1, 2000; 47(5): 685 - 688.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. VENUTI, D. SALANI, V. MANNI, F. POGGIALI, and A. BAGNATO
Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy
FASEB J, November 1, 2000; 14(14): 2277 - 2283.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
F. Vacca, A. Bagnato, K. J. Catt, and R. Tecce
Transactivation of the Epidermal Growth Factor Receptor in Endothelin-1-induced Mitogenic Signaling in Human Ovarian Carcinoma Cells
Cancer Res., September 1, 2000; 60(18): 5310 - 5317.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. I. Ahmed, J. Thompson, J. M. Coulson, and P. J. Woll
Studies on the Expression of Endothelin, Its Receptor Subtypes, and Converting Enzymes in Lung Cancer and in Human Bronchial Epithelium
Am. J. Respir. Cell Mol. Biol., April 1, 2000; 22(4): 422 - 431.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Lahav, G. Heffner, and P. H. Patterson
An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo
PNAS, September 28, 1999; 96(20): 11496 - 11500.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.